iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $100.65, for a total transaction of $503,250.00. Following the transaction, the chief executive officer owned 2,262,500 shares in the company, valued at approximately $227,720,625. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

iRadimed Price Performance

Shares of NASDAQ IRMD opened at $99.84 on Wednesday. The company has a 50-day moving average price of $96.72 and a 200-day moving average price of $80.57. The stock has a market capitalization of $1.27 billion, a P/E ratio of 60.51 and a beta of 1.09. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $104.93.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.04. The business had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities research analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Analyst Ratings Changes

Several equities analysts have weighed in on IRMD shares. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Roth Mkm set a $90.00 price target on shares of iRadimed in a research report on Friday, October 31st. Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Finally, Lake Street Capital reissued a “buy” rating and set a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.00.

Institutional Trading of iRadimed

Large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of iRadimed by 4.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 267 shares during the period. CWM LLC raised its stake in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares during the period. Farther Finance Advisors LLC raised its stake in iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the period. State of Alaska Department of Revenue lifted its holdings in iRadimed by 187.4% during the fourth quarter. State of Alaska Department of Revenue now owns 1,900 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 1,239 shares during the last quarter. Finally, Yorktown Management & Research Co Inc bought a new position in iRadimed during the fourth quarter worth about $219,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.